EOFlow’s European Partner...
▶Live photos from the EASD 2022 included EOFlow Co., Ltd., a provider of wearable drug delivery solutions, announced that its European exclusive distributing partner A. Menarini Diagnostics (‘Menarini’) showcased its tubeless, wearable, and disposable insulin pump “EOPatch” ...
Sep.23.2022
EOPatch free trial offer ...
EOFlow is pleased to inform that EOPatch free trial offer for August has been completed successfully! Read the full press release here (Korean only): http://eoflow.com/news/news_010100.html?bmain=view&uid=124 In short, for this free trial, two additional patches were specially presented, ...
Sep.14.2022
EOFlow’s Innovative Weara...
▶ Fast product approval after signing the exclusive distribution agreement with GulfDrug in GCC 6 countries in March ▶ 1 in 6 adults has diabetes in the UAE – EOFlow targets the Middle East diabetes market with high growth potential EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a ...
Sep.01.2022
EOFlow Reports First Half...
▶ Menarini will officially launch EOPatch in Europe on September 1, 2022 ▶ EOFlow expects revenue growth in the second half from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions with i...
Aug.16.2022
Menarini to Officially La...
▶ EOPatch will sell under A. Menarini Diagnostics’ diabetes care brand ‘GlucoMen Day PUMP’ ▶ Expects to expand the user base in Europe where large diabetic population live EOFlow Co., Ltd., a provider of wearable drug delivery solutions, announced on August 11 that its European pa...
Aug.11.2022
EOFlow Seeks Global Partn...
EOFlow Co., Ltd., a provider of wearable drug delivery solutions, has announced today that it presented a session and had business partnership meetings at '2022 German-Korean Business Forum in KAIST'. The forum was held by the Ministry of Science and ICT (MSIT), KAIST (Korea Advanced Instit...
Jun.16.2022
[DB Financial Investment]...
Dear investors, DB Financial Investment has published an analyst report today on June 14th. Senior researcher Jay Yoo in healthcare/growth industry covers rapidly growing global diabetes market and devices in glucose diagnosis to glucose management in the report. Analyst Yoo introduced...
Jun.14.2022
EOFlow Announces First Pa...
▶ “EOPatch X” is a two-part wearable artificial pancreas (AP) solution that automatically adjusts insulin delivery based on the user’s glucose level ▶ A multicenter trial that will be conducted at nine university-hospitals and will enroll over one hundred people with type 1 diabete...
May.20.2022
EOFlow Officially Launche...
▶ iOS version of the world’s first app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable controller with a smartphone app EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it offic...
May.17.2022
EOFlow Announces Record R...
▶ Highest-ever quarterly revenue! Strong revenue growth from European sales; Menarini will progressively launch the product in Europe from 2Q22 onwards! ▶ EOFlow expects significant growth in revenue in 2022 from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 29...
May.16.2022
